Assignment on Anticholinergics
Assignment on Anticholinergics
1. Introduction
Anticholinergics represent a pivotal class of pharmacological agents that exert their
effects by antagonizing the action of acetylcholine (ACh) at muscarinic receptors.
Acetylcholine, a primary neurotransmitter, plays a crucial role in both the central and
peripheral nervous systems, particularly within the parasympathetic nervous system,
which governs involuntary functions like digestion, salivation, micturition, and pupillary
constriction. By inhibiting these parasympathetic nerve impulses, anticholinergic drugs
effectively modulate a wide array of physiological processes, leading to diverse
therapeutic applications as well as a characteristic spectrum of side effects. The
understanding of anticholinergic pharmacology is fundamental for students in medical
and paramedical fields, including Medical Laboratory Technology (MLT), pharmacy,
nursing, and medicine, given their broad utility in managing various clinical conditions
from respiratory disorders to neurological diseases.
Historically, the effects of anticholinergic compounds were first observed with natural
plant alkaloids such as atropine from the deadly nightshade (Atropa belladonna) and
scopolamine from Hyoscyamus niger. These compounds have been recognized for
centuries for their potent physiological effects, leading to their eventual isolation and
therapeutic application. Modern pharmacology has since developed a variety of
synthetic anticholinergics, many with more selective actions, to minimize unwanted side
effects and enhance therapeutic efficacy for specific conditions. This document aims to
provide a comprehensive overview of anticholinergics, covering their mechanisms,
types, clinical uses, adverse effects, and crucial considerations for their safe and
effective administration.
2. Mechanism of Action
Anticholinergics primarily exert their therapeutic and adverse effects by competitively
blocking the binding of acetylcholine to **muscarinic receptors**. These G protein-
coupled receptors are widely distributed throughout the body and are classified into five
subtypes (M1 to M5), each with distinct physiological roles and anatomical distributions.
By preventing ACh from binding, anticholinergics effectively reduce parasympathetic
tone, leading to effects such as decreased glandular secretions, relaxation of smooth
muscles, increased heart rate, and mydriasis (pupil dilation).
• M1 receptors: Predominantly found in the central nervous system (CNS),
autonomic ganglia, and gastric glands. Blocking M1 receptors in the CNS can
lead to cognitive effects, while their blockade in the stomach reduces gastric acid
secretion.
• M2 receptors: Primarily located in the heart, where their activation by ACh slows
heart rate and reduces myocardial contractility. Antagonism of M2 receptors by
anticholinergics results in an increase in heart rate (tachycardia).
• M3 receptors: Widely distributed on smooth muscle cells (e.g., in the
gastrointestinal tract, bronchi, bladder, eyes) and glands (e.g., salivary, bronchial,
sweat glands). Blocking M3 receptors leads to smooth muscle relaxation
(bronchodilation, bladder relaxation, reduced gut motility) and reduced glandular
secretions (dry mouth, dry eyes).
• M4 & M5 receptors: Primarily found in the central nervous system, where their
precise roles are still under active investigation but are thought to be involved in
modulating neurotransmission, movement, and cognition. Some anticholinergics,
particularly those used for Parkinson's disease, target these CNS receptors.
The selectivity of an anticholinergic drug for specific muscarinic receptor subtypes can
influence its clinical applications and side effect profile. For instance, drugs with higher
affinity for M3 receptors in the lungs are preferred for respiratory conditions to maximize
bronchodilation while minimizing cardiac effects from M2 receptor blockade.
3. Types of Anticholinergics
Anticholinergics can be broadly categorized into naturally occurring alkaloids and
synthetic compounds, each with varying degrees of selectivity and pharmacokinetic
properties.
3.1. Natural
These are derived from plants, primarily from the Solanaceae family.
• Atropine: A non-selective muscarinic antagonist, historically one of the first
anticholinergics identified. It is used as an antidote for organophosphate
poisoning, to increase heart rate in bradycardia, and to reduce secretions during
surgery. Its rapid onset and potent effects make it a cornerstone in emergency
medicine.
• Scopolamine (Hyoscine): Also a non-selective muscarinic antagonist, but with
more pronounced CNS effects than atropine, particularly its anti-emetic and
sedative properties. It is commonly used for motion sickness and in palliative
care to reduce secretions.
3.2. Synthetic
These compounds are chemically synthesized and often designed to have more specific
actions or improved pharmacokinetic profiles, such as longer duration of action or
reduced systemic absorption when administered locally.
• Ipratropium: A quaternary ammonium derivative, making it poorly absorbed
systemically. It acts as a non-selective muscarinic antagonist primarily on M1,
M2, and M3 receptors. It is delivered via inhalation for bronchodilation in asthma
and COPD, with minimal systemic side effects.
• Tiotropium: A long-acting muscarinic antagonist (LAMA) with high M1 and M3
receptor affinity. Its prolonged duration of action allows for once-daily dosing,
making it highly effective for maintenance therapy in COPD.
• Glycopyrrolate: Another quaternary ammonium compound that does not cross
the blood-brain barrier readily. It is used parenterally to reduce salivation and
respiratory secretions during surgery, and orally for excessive salivation
(sialorrhea) or peptic ulcers.
• Oxybutynin: Primarily an M3 selective antagonist, commonly used orally or
transdermally to treat overactive bladder symptoms by relaxing detrusor muscle
spasms.
• Tolterodine, Solifenacin, Darifenacin, Fesoterodine: Newer synthetic
anticholinergics also primarily used for overactive bladder, often with improved
M3 selectivity or different pharmacokinetic profiles to reduce side effects
compared to older agents.
• Benztropine, Trihexyphenidyl: Primarily M1 selective antagonists used in
Parkinson's disease to reduce tremors and rigidity, counteracting the relative
excess of cholinergic activity in the basal ganglia.
The choice between natural and synthetic anticholinergics, and amongst the synthetic
agents, often depends on the desired therapeutic effect, the need for receptor
selectivity, and the acceptable side effect profile for a given patient.
4. Medical Uses
Anticholinergics are versatile drugs employed across a wide spectrum of medical
conditions due to their ability to modulate parasympathetic activity.
Mechanism /
Clinical
Condition Drug Example Purpose Rationale
Asthma / COPD Ipratropium, Bronchodilation Block M3
Tiotropium receptors on
bronchial
smooth muscle,
leading to
relaxation and
widening of the
airways.
Particularly
effective for
COPD and in
patients who
cannot tolerate
beta-agonists.
Mechanism /
Clinical
Condition Drug Example Purpose Rationale
Overactive Oxybutynin, Relax bladder Block M3
bladder (OAB) Tolterodine, muscles, reduce receptors in the
Solifenacin urgency detrusor muscle
of the bladder,
inhibiting
involuntary
contractions that
cause urgency,
frequency, and
incontinence.
Motion sickness Scopolamine Anti-nausea, Acts on M1
/ Nausea anti-emetic receptors in the
vestibular nuclei
and reticular
formation in the
brain, inhibiting
pathways that
trigger nausea
and vomiting
from motion.
Often
administered via
a transdermal
patch.
Bradycardia Atropine Increase heart Blocks M2
(slow heart rate) rate receptors in the
sinoatrial (SA)
node and
atrioventricular
(AV) node,
increasing
impulse
conduction and
heart rate.
Crucial in
advanced
cardiac life
support (ACLS)
protocols.
Parkinson’s Benztropine, Reduce tremors Primarily block
disease Trihexyphenidyl and rigidity M1 receptors in
the basal
Mechanism /
Clinical
Condition Drug Example Purpose Rationale
ganglia,
restoring the
balance
between
dopamine and
acetylcholine in
the nigrostriatal
pathway, which
is disrupted in
Parkinson's.
More effective
for tremor and
rigidity than
bradykinesia.
Peptic Ulcer Pirenzepine (M1 Reduce gastric Blocks M1
Disease selective) acid secretion receptors on
(historical) parietal cells,
reducing
acetylcholine-
stimulated acid
secretion.
Largely
replaced by
proton pump
inhibitors (PPIs)
and H2 blockers
due to better
efficacy and
fewer side
effects.
Ophthalmic Atropine, Mydriasis (pupil Block M3
Procedures Cyclopentolate, dilation), receptors in the
Tropicamide Cycloplegia iris sphincter
(paralysis of muscle and
ciliary muscle) ciliary muscle,
respectively.
Used for
funduscopic
examination, to
relieve ciliary
spasm in
uveitis, and to
Mechanism /
Clinical
Condition Drug Example Purpose Rationale
prevent
synechiae.
Preoperative Glycopyrrolate, Reduce salivary Blocks M3
Medication Atropine and bronchial receptors in
secretions exocrine glands.
Administered
before surgery
to prevent
aspiration of
secretions
during
anesthesia and
to counteract
vagal
stimulation.
5. Pharmacokinetics and Pharmacodynamics
The pharmacokinetic profile (absorption, distribution, metabolism, excretion - ADME)
and pharmacodynamic characteristics (drug action and effects) of anticholinergics vary
significantly depending on their chemical structure, particularly whether they are tertiary
amines or quaternary ammonium compounds. This influences their bioavailability, ability
to cross the blood-brain barrier, and duration of action.
• Absorption: Tertiary amines (e.g., atropine, scopolamine, oxybutynin) are well
absorbed orally and across mucous membranes due to their lipid solubility.
Quaternary ammonium compounds (e.g., ipratropium, glycopyrrolate) are poorly
absorbed orally and systemically, which is advantageous for local delivery (e.g.,
inhalation for respiratory conditions) as it minimizes systemic side effects.
• Distribution: Lipid-soluble tertiary amines readily cross the blood-brain barrier,
leading to central nervous system effects (e.g., sedation, confusion). Quaternary
ammonium compounds are highly ionized and do not readily cross the blood-
brain barrier, thus exhibiting fewer CNS side effects.
• Metabolism: Many anticholinergics undergo hepatic metabolism, primarily via
cytochrome P450 enzymes. Genetic polymorphisms in these enzymes can lead
to individual variations in drug response and side effect susceptibility.
• Excretion: Primarily excreted unchanged or as metabolites via the kidneys.
Renal impairment can significantly prolong the half-life and increase the risk of
toxicity, especially for renally cleared drugs like solifenacin.
• Pharmacodynamics: Anticholinergics act as competitive antagonists, meaning
their effects can be overcome by increasing the concentration of acetylcholine.
The magnitude of their effect is dose-dependent, and the duration of action
varies from a few hours (e.g., atropine, ipratropium) to 24 hours (e.g., tiotropium).
6. Side Effects
The adverse effects of anticholinergics are a direct consequence of their widespread
blockade of muscarinic receptors throughout the body. These effects can significantly
impact patient compliance and quality of life, particularly in elderly or vulnerable
populations.
• Dry mouth (xerostomia): Due to reduced salivary gland secretions (M3
blockade). This is one of the most common and bothersome side effects.
• Blurred vision / Mydriasis: Caused by paralysis of the ciliary muscle (M3
blockade, cycloplegia) and dilation of the pupil (M3 blockade in iris sphincter).
• Constipation: Reduced gastrointestinal motility and secretions (M3 blockade in
gut smooth muscle).
• Urinary retention: Relaxation of the detrusor muscle of the bladder (M3
blockade) leading to difficulty in urination, especially in men with benign prostatic
hyperplasia (BPH).
• Tachycardia: Increased heart rate due to blockade of M2 receptors in the heart.
More prominent with non-selective agents like atropine.
• CNS effects (especially in elderly): Drowsiness, confusion, delirium,
hallucinations, agitation, memory impairment. These are more common with lipid-
soluble tertiary amines that cross the blood-brain barrier (e.g., oxybutynin,
atropine, scopolamine). This is of particular concern in the elderly, contributing to
falls and cognitive decline (anticholinergic burden).
• Anhidrosis (decreased sweating): Blockade of M3 receptors in sweat glands,
which can lead to hyperthermia, especially in warm environments or during
physical activity.
A commonly used mnemonic to remember the peripheral anticholinergic side effects is:
“Dry as a bone (dry mouth, anhidrosis), blind as a bat (blurred vision, mydriasis), hot
as a hare (hyperthermia), red as a beet (flushing due to vasodilation to dissipate heat),
mad as a hatter (CNS effects like confusion, delirium).”
7. Contraindications
Due to their physiological effects, anticholinergics are contraindicated or should be used
with extreme caution in certain patient populations to avoid exacerbating underlying
conditions or precipitating severe adverse events.
• Glaucoma (especially angle-closure type): Anticholinergics cause mydriasis,
which can narrow the anterior chamber angle and precipitate an acute angle-
closure glaucoma attack, leading to a rapid increase in intraocular pressure and
potentially permanent vision loss.
• Benign Prostatic Hyperplasia (BPH) with urinary retention: By relaxing the
detrusor muscle and tightening the bladder neck, anticholinergics can worsen
urinary outflow obstruction and lead to complete urinary retention in men with
enlarged prostate glands.
• Myasthenia Gravis: This autoimmune neuromuscular disorder is characterized
by a reduction in nicotinic acetylcholine receptors at the neuromuscular junction.
While muscarinic receptors are less directly involved in muscle movement,
anticholinergics can exacerbate muscle weakness and lead to cholinergic crisis-
like symptoms due to their impact on autonomic regulation.
• Elderly patients: Higher risk of delirium, cognitive impairment, falls, and
anticholinergic toxicity due to altered pharmacokinetics (reduced renal clearance,
increased sensitivity) and polypharmacy leading to cumulative anticholinergic
burden.
• Severe ulcerative colitis / Toxic megacolon: Anticholinergics can inhibit gut
motility, potentially leading to ileus or exacerbating toxic megacolon, a life-
threatening complication.
• Tachyarrhythmias: Due to their ability to increase heart rate, anticholinergics
should be used cautiously in patients with pre-existing tachyarrhythmias or
unstable cardiovascular conditions.
8. Anticholinergic Toxicity
Anticholinergic toxicity, also known as anticholinergic syndrome, occurs when there is
an excessive blockade of muscarinic receptors, either due to overdose (accidental or
intentional), drug interactions, or increased sensitivity in certain individuals. It is a
medical emergency requiring prompt recognition and management.
Symptoms:
The symptoms of anticholinergic toxicity are a severe exaggeration of the typical side
effects and can range from mild to life-threatening.
• Peripheral signs:
– Flushing (red as a beet) due to cutaneous vasodilation.
– Hyperthermia (hot as a hare) due to anhidrosis.
– Mydriasis (dilated pupils, blind as a bat) with non-reactive pupils to light.
– Dry mucous membranes (dry as a bone), absent bowel sounds, severe
constipation.
– Urinary retention.
– Tachycardia, sometimes with arrhythmias.
• Central nervous system (CNS) signs:
– Agitation, restlessness.
– Confusion, disorientation, memory impairment.
– Delirium, hallucinations (visual and auditory), paranoid delusions (mad as
a hatter).
– Ataxia (uncoordinated movements).
– Muscle twitching, myoclonic jerks.
– Severe cases: Seizures, coma, respiratory depression.
Treatment:
Management of anticholinergic toxicity is primarily supportive, with the judicious use of
an antidote when indicated.
• Supportive care:
– Airway, breathing, circulation (ABC) assessment and support.
– Cooling measures for hyperthermia (e.g., cooling blankets, fan, lukewarm
sponges).
– Sedation with benzodiazepines (e.g., lorazepam, midazolam) for agitation,
seizures, or severe delirium. Avoid phenothiazines as they have
anticholinergic properties.
– Gastric lavage or activated charcoal if ingestion was recent (within 1-2
hours) and the patient is conscious and cooperative.
– Catheterization for urinary retention.
– Intravenous fluids for dehydration.
• Specific Antidote – Physostigmine:
– Mechanism: Physostigmine is a reversible cholinesterase inhibitor that
increases the concentration of acetylcholine at both muscarinic and
nicotinic receptors in the central and peripheral nervous systems. Unlike
other cholinesterase inhibitors, it can cross the blood-brain barrier.
– Indications: Used for severe anticholinergic toxicity, particularly when
marked CNS symptoms (severe delirium, hallucinations, seizures) or
refractory tachyarrhythmias are present and do not respond to supportive
measures.
– Dosage & Administration: Administered slowly intravenously (0.5 to 2
mg in adults, 0.02 mg/kg in children) over 5 minutes to avoid rapid
cholinergic effects. Can be repeated every 10-30 minutes if needed.
– Precautions: Should be used with caution and only in a monitored setting
due to potential for adverse effects such as bradycardia, asystole,
seizures (if administered too rapidly), and cholinergic crisis (nausea,
vomiting, diarrhea, increased secretions). Contraindicated in patients with
tricyclic antidepressant overdose due to increased risk of cardiac
arrhythmias.
Early diagnosis and aggressive supportive care are crucial in managing anticholinergic
toxicity and preventing severe complications.
9. Clinical Considerations & Special Populations
The use of anticholinergics requires careful consideration in various patient populations
due to altered drug metabolism, increased sensitivity to side effects, or drug-drug
interactions.
9.1. Geriatric Patients
Elderly individuals are particularly susceptible to anticholinergic side effects due to age-
related physiological changes, including reduced renal and hepatic function, increased
blood-brain barrier permeability, and a higher prevalence of comorbidities and
polypharmacy. They are at elevated risk for:
• Cognitive Impairment and Delirium: Even at therapeutic doses,
anticholinergics can precipitate or worsen cognitive dysfunction, memory loss,
and acute confusional states (delirium), often leading to hospitalizations and
long-term cognitive decline. This is due to reduced cholinergic neurotransmission
in the brain.
• Falls: Dizziness, blurred vision, and altered gait secondary to anticholinergic
effects increase the risk of falls in the elderly.
• Urinary Retention and Constipation: These issues are often exacerbated in
elderly men with BPH and in all elderly due to age-related changes in bladder
and bowel function.
The concept of "anticholinergic burden" refers to the cumulative anticholinergic effects
from all medications a patient is taking, including those not primarily classified as
anticholinergics (e.g., certain antihistamines, antidepressants, antipsychotics). Tools like
the Anticholinergic Cognitive Burden (ACB) Scale are used to assess this risk.
Prescribers should always aim to use the lowest effective dose and consider
alternatives in this population.
9.2. Pediatric Patients
The use of anticholinergics in children requires careful dosing and monitoring. Infants
and young children are more susceptible to hyperthermia due to immature
thermoregulatory mechanisms, increasing the risk of "atropine fever" from anhidrosis.
Atropine is used in specific pediatric conditions, such as reducing secretions during
anesthesia or in bradycardia. Scopolamine patches are sometimes used for motion
sickness in older children. Many anticholinergics for overactive bladder are also
approved for pediatric use, but with strict weight-based dosing.
9.3. Patients with Renal or Hepatic Impairment
Since many anticholinergics are metabolized by the liver and/or excreted by the
kidneys, dose adjustments may be necessary in patients with significant renal or hepatic
dysfunction. Impaired clearance can lead to drug accumulation and an increased risk of
toxicity. For example, solifenacin and oxybutynin metabolism can be affected by liver
impairment, while their elimination can be prolonged in renal insufficiency.
9.4. Drug Interactions
Combining anticholinergics with other medications that have anticholinergic properties
(e.g., tricyclic antidepressants, first-generation antihistamines, antipsychotics like
clozapine, certain anti-parkinsonian drugs) can lead to additive anticholinergic effects
and significantly increase the risk of adverse events, particularly CNS toxicity.
10. Conclusion
Anticholinergic drugs represent a diverse and therapeutically significant class of agents
that modulate the parasympathetic nervous system by blocking muscarinic
acetylcholine receptors. Their ability to induce bronchodilation, reduce secretions, relax
smooth muscles, and influence cardiac and neurological functions makes them
invaluable in managing a wide array of conditions, including respiratory diseases,
urinary disorders, Parkinsonism, and certain cardiovascular emergencies. However,
their broad spectrum of action also accounts for a characteristic and often bothersome
profile of side effects, ranging from dry mouth and blurred vision to potentially severe
cognitive impairment and life-threatening toxicity.
Effective and safe utilization of anticholinergics necessitates a thorough understanding
of their specific mechanisms of action, pharmacokinetic profiles, and the nuances of
their side effects and contraindications. Particular vigilance is required in vulnerable
populations, notably the elderly, where the risk of cognitive decline, falls, and cumulative
anticholinergic burden is significantly elevated. As pharmacological research continues,
the development of more selective anticholinergic agents or novel therapeutic strategies
may help to maximize therapeutic benefits while minimizing off-target effects. Ultimately,
individualized patient assessment, careful drug selection, appropriate dosing, and
vigilant monitoring are paramount to harnessing the therapeutic potential of
anticholinergics while safeguarding patient well-being.
11. References
1. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics. (Current
Edition). McGraw-Hill Education.
2. Rang and Dale’s Pharmacology. (Current Edition). Churchill Livingstone.
3. Katzung, B. G. (Current Edition). Basic & Clinical Pharmacology. McGraw-Hill
Education.
4. By the American Geriatrics Society 2019 Beers Criteria® Update Expert Panel.
American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially
Inappropriate Medication Use in Older Adults. Journal of the American Geriatrics
Society, 67(4), 674–694.
5. Taylor, P. (2006). Anticholinesterase Agents. In L. L. Brunton, J. S. Lazo, & K. L.
Parker (Eds.), Goodman & Gilman’s The Pharmacological Basis of Therapeutics
(11th ed., pp. 191–207). McGraw-Hill.
6. [Link] (National Center for Biotechnology Information)
7. WHO Drug List and Guidelines.